Board Members

Elected 2018

During David Pyott's 17-year tenure, Allergan was transformed from a small eyecare business with about $1 billion in sales to a global specialty pharmaceutical and medical device company with sales over $7 billion in 2014 and with most of the increase stemming from organic growth. Allergan's market capitalization increased from $2.3 billion in 1998 to $72 billion when Allergan was acquired by Actavis in 2015. Subsequently, the company was renamed Allergan PLC. Pyott was recognized by Harvard Business Review as one of "The 100 Best Performing CEOs in the World" in 2014 (ranked No. 4). He has lived in 10 countries and worked in seven countries in the U.S., Europe, and Asia.

In 2006, Pyott was bestowed the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty The Queen. Pyott holds a diploma in international and European law from the Europa Institute at the University of Amsterdam, a Master of Arts and honorary degree in medicine from the University of Edinburgh, and a Master of Business Administration from the London Business School. He also has an honorary degree in pharmaceutical sciences from Chapman University. Pyott is a member of the boards of Alnylam Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., and a member of the supervisory board of Royal Philips of the N.V. He is Chairman of the London Business School and Director of Pliant Therapeutics Inc. He is involved with the boards of many U.S. and international eyecare charities. In 2020, he was elected as the Hospitaller of the U.S. Priory of the Order of the Knights of St. John.

Standing Committees: Executive; Audit, Compliance and Risk, chair; Executive Compensation; JPL, ex-officio